About the THRIVE study
About the THRIVE Clinical Study
Viridian Therapeutics is developing VRDN-001 as a potential new treatment for people living with TED. VRDN-001 is an investigational drug that can be used only in the setting of a clinical study.
THRIVE
THRIVE is an ongoing clinical study of a potential treatment for people who have been diagnosed with moderate to severe active TED within the past 15 months.
In THRIVE, a trained professional administers the study drug by infusion through a vein in your arm.
What happens if I volunteer to participate?
If you volunteer to participate, the study doctor and staff will conduct initial tests to ensure you qualify.
- If you qualify, you will receive 5 infusions of either VRDN-001 or an inactive liquid called a placebo three weeks apart.
- 2/3 of participants will receive 5 infusions of VRDN-001
- 1/3 of participants will receive 5 infusions of placebo
- After the infusions are complete:
- Those who do not respond (because they received placebo or did not experience sufficient benefit from the study drug) will be offered participation in an open-label study, in which VRDN-001 will be administered
- All others will be followed for a total of one year.
- If convenient, some visits may be performed by a health care professional at your home.
If you participate you will start study treatment without waiting for insurance approvals and without any co-pays. All study-related medical tests and monitoring will be conducted by a medical professional with extensive TED experience, at no expense to you. Some travel and study-related costs may be reimbursed. THRIVE participants must meet certain requirements, referred to as eligibility criteria, and be available to receive the necessary treatments.
Is there a THRIVE clinical study site near me?
The ongoing THRIVE clinical study is being conducted at multiple sites throughout the United States.